Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumors

Eitemau Tebyg

• A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)
  gan: Pavlina Spiliopoulou, et al.
  Cyhoeddwyd: (2024-04-01)
• 3373 Modulation of Hedgehog Signaling Alters Immune Infiltration in Pancreatic Cancer
  gan: Nina Steele, et al.
  Cyhoeddwyd: (2019-03-01)
• Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
  gan: Longfei Zhang, et al.
  Cyhoeddwyd: (2022-03-01)
• Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study
  gan: Blagden, SP, et al.
  Cyhoeddwyd: (2018)
• Pharmacodynamics, chiral pharmacokinetics and PK–PD modelling of ketoprofen in the goat
  gan: Abdul Kadir, Arifah, et al.
  Cyhoeddwyd: (2003)